A series of 5␣-androst-3-enes and 3␣,4␣-epoxy-5␣-androstanes were synthesized and tested for their abilities to inhibit aromatase in human placental microsomes. In these series the original C-17 carbonyl group was replaced by hydroxyl, acetyl and hydroxyimine groups.
Introduction
Hormone-dependent breast tumors require estrogens for their growth [1] . Two main approaches have been applied to block estrogen action. One acts directly at the estrogen receptor, by means of selective estrogen receptor modulators (SERMs) and other targets aromatase, a cytochrome P-450 enzyme (CYP19), responsible for estrogen biosynthesis [2] . In breast cancer, intratumoral aromatase is the source for local estrogen production and inhibition of this enzyme is an important approach for reducing tumor growth. Tamoxifen, the most well-known SERM, has been considered the gold standard of endocrine therapy in hormone-dependent breast cancer. Nowadays, it is being taken over by aromatase inhibitors (AIs)
Fig. 1 -Steroidal aromatase inhibitors.
Despite the success of the third-generation steroidal and nonsteroidal AIs, they still have some major side effects, such as the increase of bone loss. For this reason, it is important to search for other potent and specific molecules with lower side effects. Moreover, understanding the interactions of new inhibitors with aromatase lead to new important information for quantitative structure-activity relationships (QSAR) that might help to elucidate the 3D structure of the enzyme. The present study may contribute for these goals.
Recently, a new series of steroids obtained from modifications in the A-and D-rings of the aromatase substrate, androstenedione, were designed, synthesized and evaluated for aromatase inhibitory activity by our group [11] . In that work, we have studied three main structural features considered important for the drug-enzyme interaction, namely the planarity of the A-ring, the 5␣-stereochemistry and the integrity of the cyclopentanone D-ring. In the present work, we have specially focused on the effect of some refined modifications in the original C-17 carbonyl group in the Dring of 5␣-androst-3-enes and 3␣,4␣-epoxy-5␣-androstanes in enzyme inhibition. In fact, some authors pointed out that modifications on C-17 carbonyl group, such as reduction to a 17␤-hydroxyl group, or deoxygenation to form a methylene group in analogs of androsta-1,4-diene-3,17-dione causes only modest decreases in apparent affinity to aromatase [12] . On the other hand, other authors referred that a 17-carbonyl group is necessary for a tight binding to aromatase of the 3-deoxyandrost-4-ene steroid analogs [13] . We are interested to know whether the substitution of the C-17 carbonyl group in 5␣-androst-3-enes and 3␣,4␣-epoxy-5␣-androstanes can affect their aromatase inhibitory activity. For this reason, two steroids, the 5␣-androst-3-en-17-one 3a and the 3␣,4␣-epoxy-5␣-androstan-17-one 4a (Scheme 1), that have previously shown to be potent aromatase inhibitors in placental microsomes [11] , are used as lead compounds. From them, two series of C-17 derivatives bearing hydroxyl (3b, 4b), acetyl (3c, 4c) and hydroxyimine groups (3d, 4d), were synthesized and their aromatase inhibitory activity evaluated.
Experimental

Chemistry
Melting points (Mps) were determined on a Reichert Thermopan hot block apparatus and were not corrected. IR spectra were recorded on a Jasco 420FT/IR Spectrometer. [14] . Compounds 3a and 4a were prepared as described [11] .
5˛-Androst-3-en-17ˇ-ol (3b)
To a solution of 5␣-androst-3-en-17-one 3a (0. 
3˛,4˛-Epoxy-5˛-androstan-17ˇ-ol (4b)
To a solution of 5␣-androst-3-en-17␤-ol 3b (300 mg, 1.09 mmol) in methylene chloride (5.0 ml), a solution of performic acid (0.15 ml of HCOOH 98-100% and 0.4 ml of H 2 O 2 35%) was added and the reaction mixture was stirred overnight until total transformation of the starting material. The reaction was worked-up by addition of methylene chloride (150 ml) and the organic layer was washed with 10% NaHCO 3 (100 ml) followed by water (4 × 100 ml). After drying the organic layer over anhydrous MgSO 4 , filtration and solvent evaporation to dryness gave the pure 4b as a white solid (293 mg, 93% 
5˛-Androst-3-en-17ˇ-yl acetate (3c)
To a solution of 5␣-androst-3-en-17␤-ol 3b (122.5 mg, 0.45 mmol) in dry pyridine (3.0 ml), acetic anhydride (0.5 ml, 5.29 mmol) was added and the reaction was stirred overnight at room temperature until all the starting material has been consumed. Methylene chloride (100 ml) was added and the organic layer was washed with 10% NaHCO 3 (2 × 100 ml), 10% HCl (2 × 100 ml) and water (2 × 100 ml), dried over anhydrous MgSO 4 , filtered and concentrated to dryness, giving 134.9 mg (95%) of the pure 3c as a white solid. Mp (ethanol) 
3˛,4˛-Epoxy-5˛-androstan-17ˇ-yl acetate (4c)
To a solution of 5␣-androst-3-en-17␤-yl acetate 3c (308 mg, 0.97 mmol) in methylene chloride (5.0 ml), a solution of performic acid (0.15 ml of HCOOH 98-100% and 0.4 ml of H 2 O 2 35%) was added and the reaction stirred overnight until complete transformation of the starting material. Methylene chloride (150 ml) was added and the organic layer was washed with 10% NaHCO 3 (2 × 100 ml), water (4 × 100 ml) and dried over anhydrous MgSO 4 . After filtration and solvent evaporation to dryness, 296 mg (92%) of the pure compound 4c was obtained as a white solid. 
5˛-Androst-3-en-17-one oxime (3d)
To a solution of 5␣-androst-3-en-17-one 3a (150 mg, 0.55 mmol) in methanol (7.0 ml), hydroxylamine hydrochloride 
3˛,4˛-Epoxy-5˛-androstan-17-one oxime (4d)
To a solution of 3␣,4␣-epoxy-5␣-androstane-17-one 4a (100 mg, 0.35 mmol) in methanol (7.0 ml), hydroxylamine hydrochloride (30.3 mg, 0.44 mmol) and CH 3 COONa·3H 2 O (59.5 mg, 0.44 mmol) were added. The reaction was stirred at 40 • C for 5 h until all the starting material has been consumed. After water addition (50 ml) the methanol was evaporated and the aqueous phase was extracted with methylene chloride (100 ml). The organic layer was then washed with NaHCO 3 10% (2 × 50 ml), water (3 × 100 ml), dried over MgSO 4 , filtered and evaporated to dryness yielding the pure compound 4d (60 mg, 57% 
Preparation of placental microsomes
Placental microsomes were obtained as described by Yoshida and Osawa [16] , with some modifications. Human placentas, obtained after delivery from a local hospital were placed in cold 67 mM potassium phosphate buffer (pH 7.4) containing 1% KCl. The cotyledon tissue was separated and homogenized in a Polytron homogenizer with 67 mM potassium phosphate buffer (pH 7.4) containing 0.25 M sucrose and 0.5 mM dithiothreitol (DTT, 1:1, w/v). The homogenate was centrifuged at 5000 × g for 30 min. The supernatant was centrifuged twice at 20,000 × g for 30 min and at 54,000 × g for 45 min to yield a microsomal pellet. The microsomes were washed and ressuspended in 67 mM potassium phosphate buffer (pH 7.4) containing 0.25 M sucrose, 20% glycerol, and 0.5 mM DTT and stored at −80 • C. All procedures were carried out at 0-5 • C. Protein content was estimated by the Bio-Rad protein assay (Bio-Rad Labs, Munich, Germany) using bovine serum albumin (BSA) as standard.
Aromatase assay procedure
Aromatase activity was measured according to Thompson 4) . The aromatase-catalyzed reaction was initiated by the addition of reduced nicotinamide adenine dinucleotide phosphate (NADPH, 150 M), and incubations were performed at 37 • C for 15 min. However, to minimize the time-dependent loss of the initial aromatization rate, 5 min incubation time was used for the kinetic studies. The reaction was terminated by addition of 250 l of 20% trichloroacetic acid. The mixture was transferred to microcentrifuge tubes containing a charcoal-dextran pellet, vortexed and incubated for 1 h. After centrifugation at 14,000 × g for 10 min, the supernatants were transferred to new charcoal-dextran pellets, incubated for 10 min and subsequently pelleted by a new centrifugation cycle. The supernatant containing the tritiated water product was mixed with a liquid scintillation cocktail from ICN Radiochemicals (Irvine, CA, USA) and counted in a liquid scintillation counter (LS-6500, Beckman Coulter, Inc., Fullerton, CA). All experiments were carried out in triplicate.
Results
Chemistry
Androstenedione 2 was prepared through oxidation of testosterone 1 (Scheme 1) with Jones Reagent and was, as expected, the only product formed in 98% yield. Clemmensen type reduction of 2 with zinc powder in acetic acid gave a mixture of 5␣-and 5␤-epimers from which the 5␣-epimer 3a was isolated by crystallization in 60% yield [11] . Borohydride reduction of 3a in methanol yielded, after work-up, 89% of the steroidal alcohol 3b. Acetylation of 3b with acetic anhydride in pyridine gave the acetyl derivative 3c in 87% yield. Treatment of 3a, 3b and 3c, in dichloromethane, with performic acid yielded the epoxide derivative 4a, 4b and 4c in 96%, 93% and 92%, respectively. Reaction of 3a and 4a with hydroxylamine hydrochloride and sodium acetate in methanol gave the oxime derivatives 3d and 4d with, respectively, 84% and 57% yield. X-ray studies by single crystal difractometry revealed, unequivocally, the E conformation of the hydroxyimine group of 3d and 4d (unpublished data). 
Biochemical properties
Inhibition of aromatase by 3a, 4a and their respective Dring modified derivatives 3b-3d and 4b-4d was evaluated in placental microsomes according to the Thompson and Siiteri method [17] . A screening assay was performed and the results are shown as percentage of inhibition for all compounds at 2 M relative to an assay in the absence of the inhibitor (Fig. 2) . To study the range of inhibitory activities for the compounds under evaluation, the well-known aromatase inhibitors formestane (4-OHA) and aminoglutethymide (AG), the first AI approved by FDA, were used as reference compounds, showing 97.0% ± 0.3 and 32.9% ± 1.8 inhibition, respectively. Among the C-17 derivatives of the ring-A epoxide series, compound 4a showed to be the most efficient steroid in inhibiting the enzyme (95.7% ± 0.3). When a hydroxyl group substituted the C-17 carbonyl group, as in 4b, the capacity to inhibit aromatase decreased to 85.9% ± 1.3. However, a more marked reduction of aromatase inhibitory activity was observed (11.7% ± 0.4) when the acetyl group, replaced the original carbonyl group, as in 4c. The replacement of the carbonyl group by a hydroxyimine group, as in 4d, resulted in a total incapacity to inhibit aromatase. Compound 3a, the lead steroid of the ring-A olefin series, showed 94.4% ± 1.2 of aromatase inhibition. Substitution of C-17 carbonyl group by the hydroxyl, acetyl and hydroxyimine groups yielding compounds 3b, 3c and 3d showed, respectively, 38.9% ± 4.3, 24.3% ± 1.6 and no inhibitory capacity.
The IC 50 determined for inhibitor 4b was 6.5 M, whereas inhibitor 3b at 30 M could not reach 50% of inhibition (Table 1) . Inhibitor 4b showed higher aromatase inhibitory activity than AG (IC 50 = 9.0 M), but lower than 4-OHA (IC 50 = 42 nM) while 3b was less efficient, in both cases. Inhibition kinetic studies for the most potent inhibitor (4b) were additionally performed using human placental microsomes. The type of binding to the active site of aromatase and the apparent inhibition constant (K i ) were determined. This steroid 4b revealed to be a competitive inhibitor, as shown in a Lineweaver-Burk plot in Fig. 3 . The K i , obtained by a Dixon plot, was 4.5 M (Fig. 4). 
Discussion
According to our previous study [11] , steroids 3a and 4a revealed to be strong aromatase inhibitors with an IC 50 of 0.225 M and 0.145 M and a K i of 0.050 M and 0.038 M, respectively. Androstenedione, the natural substrate of the enzyme, showed a K m of 0.0575 M. These two compounds bind the enzyme in a competitive type-manner and with a slightly higher affinity than androstenedione (respectively, 1.15 and 1.51 times more for inhibitors 3a and 4a) proving that the C-3 carbonyl group, present in the natural substrate of the enzyme and in many other aromatase inhibitors, is not essential for the enzyme-inhibitor interaction and inhibition. However, the results obtained in the present work show that unlike C-3 carbonyl, the C-17 carbonyl group present in the 5␣-androst-3-ene and 3␣,4␣-epoxy-5␣-androstane derivatives seems to be fundamental to reach maximum aromatase inhibitory activity. Modification of C-17 carbonyl group of 3a, such as reduction to a 17␤-hydroxyl group (3b), dramatically reduced the capacity of aromatase inhibition. The same type of chemical transformation performed in inhibitor 4a to give 4b showed only a modest reduction of aromatase inhibitory activity, but a considerable decrease in affinity to aromatase, from K i = 0.038 M in 4a to K i = 4.5 M in 4b. In fact, the substitution of a carbonyl group, which is a proton acceptor by a hydroxyl group, which is a proton donor, could interfere with the anchoring of the D-ring by the hydrophilic residue of the active site, which is believed to establish a hydrogen bond with C-17 carbonyl group. The same behavior was observed by Numazawa et al. with 3-deoxyandrost-4-ene steroid analogs [13] . Furthermore, according to a recent model of the active site of aromatase [19] , and a new clamping mechanism of substrate binding to the active site of aromatase [20] , the steroidal D-ring must be anchored by Van der Walls forces through hydrophobic residues, such as I133 and F134, in the B -C loop of aromatase binding pocket. These residues are described as providing hydrophobic interactions with steroid inhibitors, stabilizing them in the active site. We believe that replacement of the C-17 carbonyl group in the D-ring of 3a/4a by the more hydrophilic hydroxyl group, as in 3b/4b, may result in destabilization of the enzyme-compound interaction, decreasing its inhibitory activity. The better aromatase inhibitory activity observed for 4b relatively to 3b could be attributed to the presence of a shared oxygen atom by the C-3 and C-4, in 4b. In fact, it is accepted that the C-3 carbonyl group of androstenedione is involved in its binding to the active site of aromatase [21, 22] . The C-3, C-4 oxygen atom of 4b could play a similar role of that of C-3 oxygen atom of androstenedione.
The introduction of an acetyl group at C-17 instead of the carbonyl group, as in 3c and 4c, leads to a more dramatic reduction of aromatase inhibitory activity. In this case, the acetyl group is, as the carbonyl group, proton acceptor but being also a bulky group, may cause steric hindrance at the enzyme active site, resulting in the observed loss of activity. Here, the C-3, C-4 oxygen atom of 4c, does not benefit the binding to aromatase. In this case, the C-17 bulky group seems to be determinant.
Finally, the substitution of the original carbonyl group by the hydroxyimine group as in 3d and 4d leads to compounds with no aromatase inhibitory activity. The hydroxyimine group is simultaneously proton donor and proton acceptor and therefore allows the establishment of hydrogen bonds with the hydrophilic residue of the aromatase active site. Nevertheless, the additional presence of a proton donor group, which confers hydrophylicity, and the steric hindrance of the hydroxyimine group may imply conformational conflicts with the enzyme active site resulting in the complete absence of aromatase inhibitory activity.
In summary, as long the steroidal five-membered Dring is present, a C-17 carbonyl group in 5␣-androst-3-ene and 3␣,4␣-epoxy-5␣-androstane series is essential to reach maximum aromatase inhibitory activity. Additionally, these compounds should not contain bulky groups in the C-17 position in order to have activity. The differences in aromatase inhibitory activity of 3b and 4b suggest that the binding geometry of the 3-deoxysteroid (3b) to the active site of aromatase would be different from that of the 3,4-epoxysteroid (4b). This is pointed out by site-directed mutagenesis and computer-assisted protein-ligand docking studies on 3a and 4a (unpublished results). The presence of an oxygen atom in the 3,4 position of 4b seems to benefit the binding to the active site. The results obtained in this study along with those already reported [11] [12] [13] , particularly those where the C-17 carbonyl group was removed resulting molecules with strong activity [12] , lead to the major conclusion that the lack of one of the two C-3 or C-17 carbonyl groups in steroidal aromatase inhibitors does not affects significantly the aromatase inhibitory activity but the lack of both affects dramatically the referred activity. This statement is reinforced by the fact that testosterone (1), which has a C-3 carbonyl and C-17 hydroxyl groups, is as good a substrate for aromatase as is androstenedione (2), which has the two C-3 and C-17 carbonyl groups. It is expected that the results of this study could help in the future design of new steroidal aromatase inhibitors as well as in the establishment of SAR and QSAR for this kind of compounds.
